<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04066179</url>
  </required_header>
  <id_info>
    <org_study_id>ILBS-AH-03</org_study_id>
    <nct_id>NCT04066179</nct_id>
  </id_info>
  <brief_title>Efficacy of Monotherapy vs Combination Therapy of Corticosteroids With GCSF in Severe Alcoholic Hepatitis Patients.</brief_title>
  <official_title>Efficacy of Monotherapy vs Combination Therapy of Corticosteroids With GCSF in Severe Alcoholic Hepatitis Patients -A Randomized Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Liver and Biliary Sciences, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Liver and Biliary Sciences, India</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The patients of Severe Alcoholic Hepatitis (SAH) will be included in study based on inclusion
      and exclusion criteria. The patients will be then randomized in 3 groups for therapy. They
      will receive either steroid or Granulocyte-Colony Stimulating Factor (GCSF) or both. They
      will be followed for atleast 90 days for improvements in symptoms and various predefined
      parameters. Primary outcome will be improvement in survival at 90 Days. Patients will be
      monitored at every follow up for disease progression and complications of therapy. The study
      results will be analyzed for differences in survival rate and complications in different
      groups to propose new therapeutic guideline in SAH patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 7, 2019</start_date>
  <completion_date type="Anticipated">February 27, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 27, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>increase in Survival at 90 days in all the groups.</measure>
    <time_frame>90 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in CTP (Child-Pugh Score) in all the groups.</measure>
    <time_frame>Day 28</time_frame>
    <description>CTP- Child-Turcotte-Pugh score ranges from 5 to 15, lowest is best and highest is worst.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in CTP (Child-Pugh Score) in all the groups.</measure>
    <time_frame>Day 180</time_frame>
    <description>CTP- Child-Turcotte-Pugh score ranges from 5 to 15, lowest is best and highest is worst.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in MELD (Model for End Stage Liver Disease) in all the groups.</measure>
    <time_frame>Day 28</time_frame>
    <description>A disease severity scoring system for adults with liver disease, designed to improve the organ allocation in transplantation based on the severity of liver disease rather than the length of time on the waiting list. A MELD score is a number that ranges from 6 to 40, based on lab tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in MELD (Model for End Stage Liver Disease) in all the groups.</measure>
    <time_frame>Day 180</time_frame>
    <description>A disease severity scoring system for adults with liver disease, designed to improve the organ allocation in transplantation based on the severity of liver disease rather than the length of time on the waiting list. A MELD score is a number that ranges from 6 to 40, based on lab tests.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">126</enrollment>
  <condition>Alcoholic Hepatitis</condition>
  <arm_group>
    <arm_group_label>Prednisolone+G-CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prednisolone 40 mg/day for initial 7 days G-CSF300 microgram daily for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prednisolone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prednisolone 40 mg/day for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Granulocytes-Colony Stimulating Factor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Granulocytes-Colony Stimulating Factor 300 mcg for 7 days followed by 300 mcg every 3 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gcsf</intervention_name>
    <description>Granulocytes-Colony Stimulating Factor 300 mcg for 7 days followed by 300 mcg every 3 days</description>
    <arm_group_label>Granulocytes-Colony Stimulating Factor</arm_group_label>
    <arm_group_label>Prednisolone+G-CSF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <description>Prednisolone 40 mg for initial 7 days</description>
    <arm_group_label>Prednisolone</arm_group_label>
    <arm_group_label>Prednisolone+G-CSF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Severe alcoholic hepatitis patients [Maddrey's score &gt; 32] aged between 18 to 65
             years.

        Exclusion Criteria:

          -  Presence of active infections

          -  Acute Gastrointestinal bleed

          -  Hepatorenal syndrome

          -  Patient unwilling

          -  Discriminant Function &gt;90

          -  Autoimmune hepatitis

          -  Hepatitis B, Hepatitis C, Human immunodeficiency Virus cases

          -  Pregnancy

          -  Hemophagocytic lymphohistiocytosis (HLH)

          -  Hb&lt;8 and baseline White Blood Cell&gt;25000
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dr Ajay Mishra, MD</last_name>
    <phone>01146300000</phone>
    <email>ajaymishrapandit@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute of Liver and Biliary Sciences</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110070</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Ajay Mishra, MD</last_name>
      <phone>01146300000</phone>
      <email>ajaymishrapandit@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 14, 2019</study_first_submitted>
  <study_first_submitted_qc>August 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 26, 2019</study_first_posted>
  <last_update_submitted>September 5, 2019</last_update_submitted>
  <last_update_submitted_qc>September 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Alcoholic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

